Jump to content Jump to main menu Jump to sub menu

Archive

17 August 2009 - QED adds Safety / Pharmacovigilance service offering

Demonstrating their appreciation of the critical importance of safety and pharmacovigilance in clinical trials, not just from a Regulatory standpoint, QED has today extended its service offering to include provision of extensive Safety and PV services, ranging from SAE & SUSAR reporting through to consultancy and training. QED’s expert Safety team can provide a centralized and highly coordinated service for global studies as well as drawing on local expertise on a country-by-country basis. Similarly to their wider service offering, QED are able to tailor their safety and PV service provision to each individual client ranging from handling high volumes of SAEs for large pharma sponsors through to acting as a complete Safety Department for smaller Biotech sponsors. QED’s Safety/PV team consists of highly experienced Senior Pharmacovigilance Specialists with on average more than 10 years industry experience

9 June 2009 - QED awarded Phase II OBGYN trial

QED is delighted to announce that it has been chosen to work on a phase II Gynaecology trial for a long-term Sponsor.  The study is anticipated to run for approximately 16 months and will include sites in Belgium, Spain and Czech Republic.  The study will investigate a new treatment aimed at improving the implantation of embryos in IVF treatment.

Thomas Ogorka, QED CEO commented “We are extremely happy that this Sponsor, with whom we have been collaborating on numerous trials over the past several years,  continues to have confidence in our ability to deliver their studies.  We remain committed to our partnership with this Sponsor and are confident of another successful outcome on this project”.

25 March 2009 - QED expands global coverage to North America

QED is pleased to announce as part of its continued global expansion, the inclusion of North America to its geographic coverage.  QED’s CEO, Thomas Ogorka, commented that “The US continues to be a world-leader in standards of care, training and expertise in healthcare with unsurpassed investment in clinical research and as part of our ongoing commitment to meeting our Sponsors needs for the conduct of clinical studies globally, the inclusion of North America is a logical step.”  QED will partner with The Harte Group, a highly innovative company, representing and managing a network of Functional Service Providers to support clinical development through the various phases of the clinical trial process.  The Harte Group’s Founder and President, Michael Harte said “It is clear that the industry is moving away from bigger, bureaucratic infrastructures to leverage the talents and expertise of smaller functional service companies”.

1 July 2009 - QED awarded pivotal phase II haematology trial

QED has been awarded a multinational Phase II clinical trial with polyclonal antibodies in patients with Idiopathic Thrombocytopenic Purpura (ITP).

ITP is an autoimmune bleeding disorder characterized by abnormally low platelet levels, making it difficult for the blood to clot normally. It is a chronic and debilitating disease, associated with increased bleeding risk and impaired quality of life.

Thomas Ogorka, QED’s CEO said “We are very pleased to assist the Sponsor with this challenging study in a rare disease such as ITP. The success of this study will be directly linked with the selection of high quality Investigators and of course our experienced study team”.

28 April 2009 - QED appears in 2009 CRO Guide

QED is pleased to announce the publication of its Talking Point article and Company profile within the 2009 CRO Guide.  In an article entitled “Innovation in Outsourcing: The CRO Franchise”, QED’s Director Business Development, Paul Thompson, explains the background to the unique and highly innovative franchise model for outsourcing clinical trials that QED is world-renowned for.  Paul commented “The CRO Guide is an essential tool for Senior Management and Outsourcing Managers within the Biopharmaceutical industry.  We are very pleased to be able to showcase our company in this highly informative publication”.  If you are interested in reading QED’s article and profile, please refer to http://viewer.zmags.com/publication/f0efb979             

2 February 2009 - QED establishes dedicated QA function

QED is pleased to announce the appointment of Pam Wilson as Qualtiy Assurance Associate (QAA).  Pam’s role will be to oversee and drive quality in all aspects of QED’s and its partners operations.  A critical part of this role will be the continued performance of audits of all third party contractors working with QED, in particular the development of our Franchise partners.